Drug Profile
Research programme: drug discovery - PCI Biotech/Phio Pharmaceuticals
Latest Information Update: 28 Jun 2021
Price :
$50
*
At a glance
- Originator PCI Biotech; RXi Pharmaceuticals
- Developer PCI Biotech; Phio Pharmaceuticals
- Class Antineoplastics; Immunotherapies; Small interfering RNA
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jun 2021 No recent reports of development identified for research development in Cancer in Norway
- 28 Jun 2021 No recent reports of development identified for research development in Cancer in USA
- 19 Nov 2018 RXi Pharmaceuticals is now called Phio Pharmaceuticals